DELIVER
An International, Double-blind, Randomised Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Morbidity and Mortality in Patients with HFpEF
- Stage
- klaar
- Medicine
- dapagliflozin
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 5 November 2018
- Last Patient In
- 31 October 2020
- Last Patient Last Visit
- 27 March 2022
National Lead
dr. C.J.W. Borleffs
Cardioloog
Office Contact
